Press Releases
GT Biopharma to Host Interim GTB-3550 TriKE™ Data Review Call with Dr. Jeffrey S. Miller on May 19, 2021 at 4:00 PM ET
GT Biopharma Reports First Quarter 2021 Results
GT Biopharma Announces Update On The Commencement Of The GTB-3550 TriKE™ Monotherapy Phase 2 Clinical Trial And Solid Tumor TriKE™ Product Candidates
GT Biopharma Announces the Appointments of Gregory Berk, M.D. to Chief Medical Officer and Jeffrey S. Miller, M.D. to Consulting Chief Scientific Officer
GT Biopharma Reports Fourth Quarter and Year End 2020 Results and Business Update
GT Biopharma Announces GTB-3550 TriKE™ Monotherapy Rescues and Restores NK Cell Immune Surveillance in Relapsed/Refractory AML and MDS Cancer Patients
GT Biopharma Announces Enrollment Of Patient 10 in GTB-3550 TriKE™ Phase I/II Clinical Trial
GT Biopharma's TriKE™ Interim Clinical Trial Results Presented At Innate Killer Summit 2021
GT Biopharma Announces Updated Interim GTB-3550 Trike™ Clinical Trial Results
